Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?

Does the LEADER trial data provide any guidance for how we might use fixed ratio combinations of basal insulin plus GLP-1 RA, or should we avoid such cross-trial comparisons?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Derek LeRoith, MD, PhD

Derek LeRoith, MD, PhD

Professor of Medicine Director of Research in the Division of Endocrinology, Diabetes and Bone Diseases Mount Sinai School of Medicine New York, New York